Basic Information
| LncRNA/CircRNA Name | ARNILA |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | triple negative breast cancer |
| ICD-0-3 | C50 |
| Methods | Microarray, qPCR, Luciferase reporter assay, Western blot, ChIP etc. |
| Sample | triple negative breast cancer tissues, cell line (MDA-MB-231 and Hs578T) |
| Expression Pattern | up-regulated |
| Function Description | We performed experiments with or without DHT treatment in three TNBC cell lines, and we identified an AR negatively induced lncRNA (ARNILA), which correlated with poor progression-free survival (PFS) in TNBC patients and promoted epithelial-mesenchymal transition (EMT), invasion and metastasis in vitro and in vivo. Subsequently, we demonstrated that ARNILA functioned as a competing endogenous RNA (ceRNA) for miR-204 to facilitate expression of its target gene Sox4, which is known to induce EMT and contribute to breast cancer progression, thereby promoting EMT, invasion and metastasis of TNBC. High ARNILA expression was correlated with poor PFS(HR, 2.72; 95%CI, 1.26?5.70; P = 0.012) in TNBC. |
| Pubmed ID | 29844570 |
| Year | 2018 |
| Title | An androgen receptor negatively induced long non-coding RNA ARNILA binding to miR-204 promotes the invasion and metastasis of triple-negative breast cancer. |
External Links
| Links for ARNILA | GenBank HGNC NONCODE |
| Links for triple negative breast cancer | OMIM COSMIC |